Table 1.
Results of Treatment With Linaclotide and Prucalopride
| Demographics |
|---|
|
24 PD – duration: 13 ± 7 years; UPDRS range: 7–60 6 non‐PD parkinsonism: 2 MSA‐ duration: 4 ± 1 years; 4 PSP – duration: 7 ± 5 years Total: 30 patients (age 67 ± 9 years; 50% female) 6 patients used both medications (linaclotide and prucalopride)* |
| Linaclotide (n = 19) | Prucalopride (n = 17) | |||||
|---|---|---|---|---|---|---|
| Treatment duration (months) | 10 ± 8 | 19 ± 18 | ||||
| Dosage |
145 μg: n = 11 290 μg: n = 4 Missing data: n = 4 |
1 mg: n = 4 2 mg: n = 8 4 mg: n = 2 Missing data: n = 3 |
||||
| Patients refractory to over‐the‐counter laxatives before starting linaclotide or prucalopride | 70% | 89% | ||||
| All patients (n = 19) | PD (n = 16) | Non‐PD (n = 3) | All patients (n = 17) | PD (n = 13): | Non‐PD (n = 4) | |
| Bowel movement frequency (per week) | ||||||
| Pre‐treatment | 1.5 (1–3; n = 10) | 1 (1–3; n = 8) | 2 (2–2; n = 2) | 1 (1–2; n = 11) | 1 (1–2; n = 9) | 1.5 (1–2; n = 2) |
| Post‐treatment | 3 (2–7; n = 11)** | 3 (2–7; n = 9)*** | 7 (7–7; n = 2) | 5 (1–7; n = 9)*** | 5 (1–7; n = 7)** | 7 (7–7; n = 2) |
| Objective improvement | ||||||
| Yes | n = 8 (42%) | n = 6 | n = 2 | n = 8 (47%) | n = 6 | n = 2 |
| No | n = 3 (16%) | n = 3 | n = 0 | n = 1 (6%) | n = 1 | n = 0 |
| Missing data | n = 8 (42%) | n = 7 | n = 1 | n = 8 (47%) | n = 6 | n = 2 |
| Subjective improvement | ||||||
| Yes | n = 13 (69%) | n = 10 | n = 3 | n = 8 (47%) | n = 6 | n = 2 |
| No | n = 4 (21%) | n = 4 | n = 0 | n = 6 (35%) | n = 5 | n = 1 |
| Missing data | n = 2 (10%) | n = 2 | n = 0 | n = 3 (18%) | n = 2 | n = 1 |
Missing data: information not documented in medical records and patient could not answer the telephone interview. One patient with SPG11 (Spastic Paraplegia 11) was initially identified but not included in the final analysis.
*Six patients in the prucalopride group were switched to linaclotide: 5 patients because of lack of efficacy and 1 due to significant headache. Among these 6 patients, 4 (67%) reported improvement with linaclotide, 1 reported no improvement and in 1 patient, data was not available. Data on bowel movement frequency are median (range).
**P < 0.01 and ***P < 0.05 (Wilcoxon signed‐rank test). Objective and subjective improvement were not significantly different between PD and non‐PD patients (P > 0.05, Fisher's exact test).
Abbreviations: MSA, Multiple System Atrophy; PD, Parkinson's disease; PSP, Progressive Supranuclear Palsy (MSA, PD, and PSP based on clinical criteria); UPDRS, Unified Parkinson's disease rating scale.